In this work, we aimed to describe, in a cohort of archival NSCLC samples, the EGFR expression and mutation status, as well as mutations in the KRAS gene and the methylation status of the potential epigenetic marker genes CDH1, CDKN2Ap16, RASSF1A, TERT, and WT1 to determine gender-specific differences. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.